Press Room

There are 3 item(s) tagged with the keyword "iCo Therapeutics".

1. iCo Therapeutics and JDRF Partnership Goes Beyond Clinical Advancement

VANCOUVER (June 5, 2013) - iCo and JDRF established a partnership in September 2011 when they joined forces on the iDEAL Study to improve outcomes for people affected by diabetic macular edema (DME).

2. iCo Therapeutics Featured in JDRF's Top Research Highlights Publication

VANCOUVER, July 3, 2012 /CNW/ - iCo Therapeutics (TSX-V: ICO), a Vancouver-based drug company, is pleased to announce that it has been featured in a JDRF newsletter entitled Top Research Highlights. JDRF is the largest charitable supporter of type 1 diabetes (T1D) and has joined force...

3. iCo Therapeutics and JDRF Team Up

March 28, 2012, Vancouver, Canada—iCo Therapeutics (TSX-V: ICO), a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common ...

Lets turn type one into type none